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Abstract
Objective: to evaluate the efficacy of tigecycline treatment in Combat-Related 
Traumatic Chronic Osteomyelitis (CRTCO). 
Methods: a retrospective study evaluates tigecycline in the treatment of CRTCO. 
Cases’ charts were reviewed for patients who were treated over the period 2011-
June 2012. During the tigecycline treatment period, orthopedic surgeons taking 
care of patients were not informed about the pending study. 
Results: ten cases were included (one female and nine males), their mean age 
45.5 years. The most bones affected with CRTCO were femur followed by tibia. 
Microbiological diagnoses were obtained mostly from culture of bone biopsies and 
bone swabs. Bacteria isolated were identified as Acinetobacter spp. [6], Klebsiella 
pneumoniae [6], Escherichia coli [5], Pseudomonas aeruginosa [4], Enterococcus 
spp. [3] and Staphylococcu saureus. The mean duration of Tigecycline treatment 
was 35.7 days (range 21-91). Patients were treated with other antimicrobials prior 
to tigecycline for extended periods. Paired difference of the ESR for eight avail-
able patients’ pair was not significant (p = 0.055), the same was observed for CRP 
(p = 0.9). There were seven (70%) clinically cured or improved patients with tige-
cycline treatment. 
Conclusion: CRTCO is a polymicrobial infection mostly caused by Gram-negative 
bacilli. The outcome of treating these patients with tigecycline is promising.
Introduction
Combat-related traumatic chronic osteomyelitis (CRTCO) 
is characterized by contaminated wounds; bones are usu-
ally shattered into many pieces, bone loss, shrapnel and the 
presence of necrotic bone and compromised soft tissues, oc-
casional sinus tract with drainage. Surgical interventions are 
frequently needed, and the majority of patients need some 
form of prosthetic hardware to stabilize fractured bones, and 
infection is frequently polymicrobial, adding to management 
difficulties. Bone biopsy for microbiological examination is of 
the utmost importance. In addition, aspiration of occasion-
ally existing fluids surrounding the inflammation would help 
in obtaining accurate microbiological diagnosis [1, 2, 3, 4].
During early 2011-June 2012, many Arab patients were re-
ferred to hospitals in Amman, Jordan for the management 
of complicated traumatic wounds with chronic osteomyeli-
tis. Some referred patients had CRTCO, mostly infected with 
polymicrobial multidrug resistant bacterial infections. The 
treatment of these patients was tedious and mostly need-
ed parenteral broad-spectrum antimicrobials for extended 
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periods. The normal accepted period of treatment for chronic 
osteomyelitis is six weeks, in conjunction with surgical de-
bridement. Although a few reports found no significant dif-
ference for regimens employed for less than six weeks. Never-
theless, the treatment duration of CRTCO remains undefined 
and controversial [5, 6, 7].
Many antimicrobials are useful in the treatment of chronic 
osteomyelits with variable success rates, whether with par-
enteral or oral agents [8, 9]. In the last decade, the introduc-
tion of tigecycline has added to the antimicrobial armamen-
tarium. Tigecycline belongs to the family of Glycylcyclines, 
a minocycline derivative, with extended-spectrum activity. 
This drug evades the resistance mechanisms that the parent 
compound was susceptible to, i.e., tetracycline-specific efflux 
pump acquisition and ribosomal change [10]. Tigecycline’s an-
timicrobial spectrum includes aerobic and anaerobic bacteria; 
including methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-intermediate S. aureus (VISA), vancomycin-resis-
tant enterococci (VRE) and penicillin-resistant Streptococcus 
pneumonaei as well as extended-spectrum beta-lactamase 
(ESBL) producing Gram-negative bacteria [10, 11]. The la-
beled indications of tigecycline include complicated abdomi-
nal infections, skin and skin structure infections and mild to 
moderate community-acquired pneumonia [12-14]. The drug 
may be suitable for use in infections with multidrug resistant 
bacteria, and it has good bone concentration as well as good 
penetration in surrounding tissues due to its large volume of 
distribution. When tested by using single dose kinetic study 
in a rabbit bone model, infected bones have significantly (P 
= 0.05) higher tigecycline concentrations [15].
This study investigates the effectiveness of tigecycline treat-
ment in those patients with CRTCO  and multidrug resistant 
(MDR) polymicrobial infections. 
Materials and Methods
Study structure and patients
A retrospective study was conducted in the Specialty teach-
ing hospital in Amman, Jordan. Patients who suffered from 
CRTCO were included. The aim was to evaluate tigecycline 
efficacy in the treatment of CRTCO. Cases were reviewed 
for all combat-traumatized patients who were admitted and 
treated over the period (2011-June 2012). Orthopedic sur-
geons taking care of patients prescribed tigecycline at their 
discretion on compassionate basis. Chronic osteomyelitis was 
defined based on criteria described by Mader et al., and by 
excluding patients who did not have diagnostic criteria of 
chronic osteomyelitis as described [1]. Clinical improvement 
was defined as a significant clinical mitigation of the patient’s 
symptoms obviating the need to continue with other anti-
microbials. Partially improved patients included those who 
had been mitigated, but judged by their orthopedic surgeon 
either not to be completely improved or were discharged 
with oral antimicrobials. Some patients were contacted by 
telephone few months after discharge and return to their 
home countries in order to follow up on their progress. Un-
improved patients were those that were switched to other 
antimicrobials. Culture specimens were collected from bone 
biopsy, bone swabs or the immediate surrounding soft tis-
sues fluid aspiration or sinus-tract cultures. Culture specimens 
were processed in the hospital microbiology laboratory by 
inoculation into thioglycolate broth and incubation for five 
days for the presence of bacterial growth; First sub culture of 
specimens from the broth was done after forty-eight hours 
of incubation by inoculation into MacConkey, chocolate agar 
and blood agar. Gram-positive bacteria colonies were test-
ed for coagulase and are further identified and by Viteck 
II. Gram-negative lactose-fermenters grown on MacConkey 
were further identified with ViteckII, whereas Non-lacose fer-
menters were identfied by oxidase reaction and then with 
Viteck II. Antibiotic susceptibility test was processed by the 
automated Viteck  II (BioMérieux SA. F-69280Marcy l’Etoile, 
France).
Statistical methods
Data were processed in Microsoft excel spread sheet. Isolated 
bacteria from different sources were considered based on the 
likelihood of the infecting pathogen/s .Odds ratio and relative 
risks were calculated for the likely isolated Gram-negative 
bacteria pathogen. SSPS was used for ESR and CRP, both 
measured before and after treatment, differences among 
each were calculated as paired ones. Two tailed t-student test 
and 95% confidence interval were calculated for the paired 
differences. Significance is considered for p< 0.05.
Results
Ten cases were included in this study (one female and 9 men), 
with a mean age of 45.5 (range 20-70) years. Bones with 
CRTCO were; femur (6) patients, tibia (3), and one others. 
Microbiological diagnosis of infected patients was obtained 
by culturing bone biopsy specimens (4), bone swabs (4) and 
sinus swab (Table 1). The following pathogens were recov-
ered; Acinetobacter spp. [6], Klebsiella    pneumonia [6], Esch-
erichia coli [5], Pseudomonas aeruginosa [4], Enterococcus 
spp. [3], Staphylococcus aureus [1] and others bacteria species 
(3) (Table 2). The mean tigecycline-treatment duration was 
35.7 days (range 21-91). All patients were on other antimi-
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Table 1. Demography and characteristics of the ten patients with chronic osteomyelitis who were treated with tigecycline.
Case Age Gender
Duration 
of 
tigecycline
Site of 
Osteomyelitis
Source of 
Culture
No. of 
Surgeries Prosthesis#
Reasons for 
switching to 
tigecycline
Improvement@
1 70 Male 21 Tibia Bone  3 No
Clinical failure and 
side effects of  
previous regimen
Yes (Partial)
2 34 Male 33* Femur Bone  9 Yes
Clinical & 
Microbiological 
failure
Yes (Partial)
3 20 Male 40 Femur Sinus  2 Yes NA Yes (Partial)
4 51 Male 21* Others Sinus  10 No Clinical failure No
5 64 Male 32 Femur Bone  3. Yes Clinical failure Yes
6 29 Male 28 Femur Bone  NA No
Clinical failure and 
side 
effects of previous 
regimen
Yes
7 59 Male 91* Tibia Bone  22 Yes Clinical failure No
8 39 Male 30* Femur Bone  9 No
Clinical failure and 
side effects 
of previous  
regimen
No
9 23 Male 19 Tibia Bone  5 No
Clinical and 
Microbiological 
Failure
Yes
10 66 Female 42* Femur Bone  1 Yes
Clinical failure and 
side effects 
of previous  
regimen
Yes
@ Refer to text under “Study structure and patients” for definition of improvement.
*  Added antimicrobials to tigecycline included: Ceftazidime, Pipracillin/tazobactam, Ciprofloxacine, Imipenem and Amikacin.
#  Prosthesis included plates, screws, intramedullary nails, wires, and external fixators
Mean and range of osteomyelitis diagnosis before switching to tigecycline: 467.37 (2 – 1825) days
Patients’ mean age and range: 45.5 (20-70) years
Mean and range duration of tigecycline treatment: 35.7 (21 -91) days
NA: Not available
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Table 3.  Number and rates of improvement in ten patients 
with chronic osteomyelitis treated with tigecycline.
Clinical Outcome* Tigecycline No. (%)
Improved 4 (40)
Improved (partial) 3 (30)
Not improved 3 (30)
*  Refer to text under “Study structure and patients”  
for definition of improvement.
Table 2.  Number and frequency of microbiological isolation and their source frequency per microorganism in patients with 
combat-related traumatic chronic osteomyelitis who were treated with tigecycline.
Microorganism Bacterial IsolatesFrequency and (%) Culture Sources
Staphylococcus aureus 1 (3.57)                   Bone Biopsy
Escherichia coli 5 (17.85)
                  Bone Biopsy 2
                  Bone Swab 2
                  Superficial Swab 1
Pseudomonas aeruginosa 4 (14.28)                   Bone Biopsy 4
Acinetobacter spp 6 (21.42)                   Bone Biopsy 4                  Bone Swab 2
Klebsiella pneumoniae 6 (21.42)
                  Bone Biopsy 4
                  Bone Swab 1
                  Sinus Swab 1
Enterococcus spp. 3 (10.71)                   Bone Biopsy 2                  Bone Swab 1
Enterobacterspp 2 (7.14)                   Bone Swab 1                  Sinus Swab1
Citrobacter spp. 1 (3.57)                   Bone Swab  
Odds ratio for encountering a gram-negative bacteria = 69.4, Relative risk = 8.3. 
Monomicrobial isolation was in one patient with E. coli and the rest of patients showed  polymicrobial growth pattern.
Polymicrobial cultures came from all sources, mostly (60%) from bone biopsy.
crobials before receiving tigecycline. Reasons for switching 
to tigecycline were due to clinical failure in all patients, in 
addition to side effects of previous regimen in four and per-
sistence of infection in other patients. ESR paired differences 
for eight available values: Mean difference 25.6, DF = 7, Two-
tailed t = 2.23, p = 0.055, 95% C.I. (- 0.73 to 51.98). Paired 
difference for CRP were; mean= 3.07, DF = 7, two-tailed 
t-test = 0.130, p = 0.9, and 95% C.I. (-53 to 59) (Table 4). 
Numbers of surgeries were variable ranging from 1 to 22 sur-
geries including major dressing and debridement in a clinically 
treatment-failed patient. Prosthesis (plates, screws, intramed-
ullary nails and external fixtures) were used in five patients, 
one was among clinical failures (Table 1). Clinically improved 
patients were seven cases (70%) and no data were available 
on follow up cultures, three of them were partially improved; 
though described as improved and were discharged on oral 
treatment (Table 3).
Discussion
War traumas usually involve fractured bones with complica-
tions including CRTCO. Caring for those patients is hampered 
by wound being contaminated by poor treatment conditions 
in the combat field and initial treatment stations. Hence, re-
ferred patients often harbor MDR organisms [4, 17]. Our pa-
tients exhibited polymicrobial infections, dominated by MDR 
Gram-negative bacteria (Table 2).
A similar study has reported that coagulase-negative staphylo-
cocci accounted for 9% of all isolates recovered from patients 
with CRTCO during the Iraqi war [16, 17]. A review article by 
Murray and Hospenthal [18] had also shown similar patterns 
of predominant Gram-negative bacterial infections to those 
reported in this study. The results of our cases demonstrate 
that seven (70%) of tigecycline-treated patients improved on 
follow-up for up to six months after end of treatment. A 
literature review of on CRTCO treatment did not reveal any 
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Table 4.  Laboratory inflammatory parameters for the ten patients with CRTCO who were treated with tigecycline, and their 
paired difference significance tested by p-value and 95% confidence interval.
Case Number ESR before treatment
ESR after 
treatment
CRP Before 
Treatment
CRP After 
Treatment WBC
1 NA NA NA NA 7.20
2 54 51.00 145.0 120.00 10.0
3 12 10.00 2.6 2.90 6.20
4$ 113 106.00 26.0 8.20 8.10
5 29 2.00 8.7 32.00 7.30
6 43 12.00 37.0 3.00 7.50
7$ 121 22.00 111.0 23.00 8.20
8$ 115 95.00 16.3 163.00 10.9
9 37 NA 3.9 NA 7.10
10 54 38.00 89.9 104.49 12.3
Paired Difference For Eight Patients With Available Paired ESR and CRP
ESR CRP
Mean for the difference 25.6 3.07 -
Degree of Freedom 7 7 -
Two tailed t-test 2.23 0.130 -
P Value 0.055 0.9 -
95% Confidence Interval - 0.73 – 52 -53 - 59 -
NA: Not available.
$: Cases clinically judged not improved.
studies addressing the treatment outcomes of different an-
timicrobials. An interesting finding in our case series is that 
there was no significant difference in paired comparisons for 
ESR (p = 0.055) and CRP (p = 0.9) in the seven patients in 
whom their clinical conditions improved completely by the 
end of therapy.
In conclusion, CRTCO is a polymicrobial infection mostly 
caused by MDR Gram-negative bacilli. The outcome of treat-
ing CRTCO with tigecycline is promising, but controlled trials 
are needed to compare the efficacy of different antimicrobi-
als in the treatment of these difficult-to-treat infections.
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